AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06202807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT00414011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
Study NCT00414011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Description: 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
Study NCT06073717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.
Study NCT06073717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor-cognitive Training
Description: Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.
Study NCT06073717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness
Description: Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.
Study NCT05469854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan glurate
Description: Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg).
Study NCT05469854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, oral tablets
Study NCT05606159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus velezensis DSM 33864
Description: 1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.
Study NCT05606159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.
Study NCT05144477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAID Fear Intervention
Description: Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
Study NCT06336174 — intervention group
Intervention type: DRUG
Intervention: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Description: All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
Study NCT06336174 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Description: All patients underwent endovascular therapy and received standard medical management after surgery, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
Study NCT04218019 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTFields
Description: The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
Study NCT06568913 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBC
Description: Platelets counts in pediatric patient with perisistent or chronicITP unresponsive to steroids
Study NCT05473247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ring-Fit Adventure Group
Description: Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.
Study NCT06568107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental And Sensory Experience (EASE) intervention
Description: The participant will be exposed to 30 minutes of a still nature image and associated nature sounds (60-80 beats per minute). An brief interview will occur with the legally authorized representative to find out what nature scene would meet the preference of the person living with dementia and persistent vocalizations.
Study NCT03850262 — intervention group
Intervention type: RADIATION
Intervention: MRI
Description: The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~* The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~* Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique.
Study NCT05775237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin Gummies
Description: Chew gummies thoroughly and completely before swallowing.
Study NCT04614519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low impact laparoscopy group
Description: Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
Study NCT04107545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: athletes
Description: Control of body temperature using the bodyCap temperature monitor that records body temperature for up to 48h (three times)
Study NCT05775237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C Gummies
Description: Chew gummies thoroughly and completely before swallowing.
Study NCT05775237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin Gummies
Description: Chew gummies thoroughly and completely before swallowing.
Study NCT05685693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted total knee arthroplasty (raTKA)
Description: Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
Study NCT05685693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional total knee arthroplasty
Description: total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
Study NCT05459961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral spermidine
Description: oral supplement
Study NCT06469905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erector Spina Plan Block
Description: ESPB will be applied to the patients in the study group. Stabilization exercises will be applied together with ESPB treatment. The needle will be inserted between the erector spinae muscle and the transverse process structures.The local anesthetic will be monitored to spread along the erector spinae muscle.
Study NCT06469905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Description: Stabilization exercises will be practiced to control group
Study NCT06058546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jiuweihuaban Pill placebo
Description: Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.
Study NCT06058546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose Jiuweihuaban Pill
Description: Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
Study NCT06058546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose Jiuweihuaban Pill
Description: High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
Study NCT06581341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation and Percutaneous Tibial Nerve Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.~Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used.
Study NCT06581341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.
Study NCT06581341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Tibial Nerve Stimulation
Description: Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used.
Study NCT05482698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-25 cream
Description: Topical application
Study NCT05482698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MC2-25 vehicle
Description: Topical application
Study NCT05154175 — intervention group
Intervention type: DEVICE
Intervention: Ottobock helmet
Description: Patients treated in current practice
Study NCT06476171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of the level of the studied biomarkers
Description: Determination of the level of hematological indices based on a general blood test; Determination of the levels of the following biomarkers: isolation of neutrophils from the blood using the gradient centrifugation method; assessment using enzyme immunoassay (ELISA) of the content of neutrophil elastase in the supernatant; myeloperoxidase, ELISA; lactoferrin, ELISA; interleukin -1ß,17,10,6, ELISA; presepsin, ELISA; endothelin, ELISA; lipopolysaccharide, LAL test; lipopolysaccharide binding protein, ELISA; NETs release, immunofluorescence method; the number of neutrophils expressing PDL-1, flow cytofluorimetry method; procalcitonin in human plasma and serum, VIDAS B.R.A.H.M.S. PCT; ferritin, reagent for determination (FERRITIN); lactate dehydrogenase, reagent for determination of QSR6128;Endotoxin Activity Assay, chemiluminescent immunodiagnostics.
Study NCT06465706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAmbre investigational device
Description: Randomized 1:1 to either experimental group or control group.
Study NCT06465706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAmbre investigational device
Description: Randomized 1:1 to either experimental group or control group.
Study NCT06536582 — intervention group
Intervention type: BIOLOGICAL
Intervention: Platelet rich growth factor injection (autologous product)
Description: All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.
Study NCT05681026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Sessions
Description: Participants will have up to 12 sessions, 3 sessions per week starting two weeks before the transplant and throughout the first 30 days of your hospitalization.
Study NCT05681026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaries
Description: Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
Study NCT05681026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interviews
Description: Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
Study NCT05521958 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acute injury without compartment syndrome
Description: Acute tibial shaft or tibial plateau fractures who do not have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken.
Study NCT05521958 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acute injury with compartment syndrome
Description: Acute tibial shaft or tibial plateau fractures who have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken.
Study NCT05521958 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exertional compartment syndrome
Description: For patients with exertional compartment syndrome, a muscle biopsy will be obtained from affected extremity.
Study NCT06567249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary hypothermia
Description: This trial stands apart from other studies of intracoronary hypothermia, mainly because it will establish the role of intracoronary hypothermia in reducing infarct size not only in the left anterior descending artery territory but in other vessels as well, including the right coronary artery and circumflex coronary artery.
Study NCT06567249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard percutaneous coronary intervention
Description: Percutaneous coronary intervention is performed in a standard manner.
Study NCT04800367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab Prefilled Syringe [Evenity]
Description: 2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
Study NCT04800367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 MG/ML Prefilled Syringe [Prolia]
Description: 1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
Study NCT06588413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Subjects will be randomized to either olanzapine 2.5 mg or 5 mg
Study NCT06588413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Subjects will be randomized to either olanzapine 2.5 mg or 5 mg
Study NCT06585943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forced Rate Exercise + Rehab
Description: The FE+rehab group (N=33) will complete FE on the cycle designed to augment pedaling rate to >75 RPM. Target heart rate zone will be set to 60-80% of HR reserve. The session will consist of a 5-min warm-up, 35-min main exercise set, and 5-min cool down. Following FE, abbreviated sessions of motor learning-based training will be administered by a neurologic OT and PT experienced in stroke rehabilitation, with 30 min focused on restoration of UE function (OT) and 15 min focused on LE motor function/ gait training (PT).
Study NCT06585943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The rehab group will receive consecutive, full-length sessions of motor learning-based training, administered by a neurologic OT and PT experienced in stroke rehabilitation, with 45 min focused on restoration of UE function (OT) and 45 min focused on LE motor function/ gait training (PT).
Study NCT06611033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V118C
Description: Intramuscular Administration
Study NCT05204524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide for injection combined with epirubicin
Description: Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
Study NCT04844281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1® Daily Disposable Toric Contact Lens
Description: Soft, toric contact lens used to correct distance vision and astigmatism.
Study NCT06611033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V118
Description: Intramuscular Administration
Study NCT06611033 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PREVNAR 20™
Description: Intramuscular Administration
Study NCT06611033 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Intramuscular Administration
Study NCT06611033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intramuscular Administration
Study NCT06081946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
Study NCT06081946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study NCT06612255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Delafloxacin tablet
Study NCT06612255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin Powder
Description: Delafloxacin powder for oral suspension formulation
Study NCT04662086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acebilustat
Description: 100 mg capsule administered orally once daily
Study NCT04662086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: 200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
Study NCT05503914 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose radiotherapy
Description: On the first and second days of induction chemotherapy, local tumor were irradiated with 0.5Gy bid for 4 times.